webinar register page

Webinar banner
Immunotherapy for Brain Tumors
Immunotherapy – particularly the use of checkpoint inhibitors – has been a revolution in cancer care. However, not all cancers respond to checkpoint inhibitors, and the response rates are only 20-30%. Given the negative results in studies to treat one of the most deadly brain tumors, glioblastomas (GBM), using checkpoint inhibitors, novel immunotherapy strategies are needed.

Current approaches have employed the concept of multimodal strategies with immunotherapy. The central concept is to cause focal disruption to “kindle” a systemic immune response. For brain tumors, modalities such as focused ultrasound, stereotactic radiosurgery, neoadjuvant surgery, and laser ablation are being combined with immunotherapy strategies in hopes of generating an antitumor immune response.

Feb 24, 2020 01:00 PM in Eastern Time (US and Canada)

* Required information


Michael Lim, MD
Dr. Michael Lim is a Professor of Neurosurgery, Oncology, Otolaryngology, and Radiation Oncology at Johns Hopkins University School of Medicine. He also directs the Brain Tumor Immunotherapy Program and Metastatic Brain Tumor Center at Johns Hopkins.